2 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow Unresectable Synovial Sarcoma: new trials by email Literature Review of Unresectable Synovial Sarcoma trials Research Report on Unresectable Synovial Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection - Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 42 | 2026-11-23 | 2026-09-25 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-10-22 |
| Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2017-12-14 | 2023-10-25 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
Sarcoma, Synovial (5) · Dermatofibrosarcoma (2) · Histiocytoma, Malignant Fibrous (2) · Liposarcoma (2) · Liposarcoma, Myxoid (2) · Sarcoma (2) · Disorders of Sex Development (1) · Fallopian Tube Neoplasms (1) · Fibrosarcoma (1) · Hemangiosarcoma (1) · Leiomyosarcoma (1) · Melanoma (1) · Mycosis Fungoides (1) · Neurofibrosarcoma (1) · Ovarian Neoplasms (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Connective Tissue (5) · Neoplasms, Connective and Soft Tissue (5) · Neoplasms, Adipose Tissue (4) · Sarcoma (3) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Gonadal Disorders (2) · Histiocytoma (2) · Liposarcoma (2) · Neoplasms, Fibrous Tissue (2) · Neoplasms, Nerve Tissue (2) · Urogenital Diseases (2)
Biopsy (2) · Doxorubicin (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Cyclophosphamide (1) · Decitabine (1) · Injections (1) · Interferon-gamma (1) · Leukapheresis (1) · interferon gamma-1b (1) · liposomal doxorubicin (1) · pembrolizumab (1) · peposertib (1) · ribociclib (1)
National Cancer Institute (NCI) (3) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1)
United States (4)
Candace L Haddox (1) · Lara E Davis (1) · Michael S Khodadoust, MD (1) · Michael Wagner (1) · Philip McCarthy, MD (1)
UM1CA186709 (2), P30CA015704 (1), P30CA016056 (1), R01CA164333 (1), U01CA154967 (1)